This activity was originally presented live at the 2025 Community Oncology Conference in Lake Buena Vista, Florida on April 29, 2025.
Program Description
Precision treatment for non-small cell lung cancer (NSCLC) relies on accurate identification of patients with biomarker alterations. These advancements in disease identification require that oncology pharmacists have a deep understanding of precision medicine for optimal patient care. However, biomarker testing practices vary by practice setting, cancer type, and mutation, with inconsistent adherence to guidelines. This session addresses the latest solutions for integrating molecular testing techniques, the interpretation of results, and the application of this information to select appropriate targeted therapies. Expert faculty will discuss resources and models for delivering precision oncology care. This program aims to equip oncology pharmacists with the tools and expertise to effectively integrate biomarker testing into their practice, ultimately improving patient outcomes in NSCLC.
Target audience: Oncology pharmacists and specialty pharmacists
Type of activity: Application
Release date: May 6, 2025
Expiration date: May 6, 2026
Time to complete activity: 0.75 hour
Learner level: Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the appropriate use of molecular testing techniques for molecular profiling in non-small cell lung cancer (NSCLC), focusing on their impact in selecting biomarker-driven therapies
- Explore evidence-based tools and resources to support the accurate interpretation of molecular profiles and inform biomarker-guided therapy choices in NSCLC treatment
- Examine real-world strategies for integrating precision medicine into standard oncology care, with emphasis on NSCLC treatment
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
